Biotech New Deal Calendar

WEEK OF OCT. 16

ASTHMATX INC. (Nasdaq: AZMA): initial public offering of 5 million shares; greenshoe of 750,000 shares available; proposed at $11 to $13 per share; Mountain View, Calif., medical devices firm has developed the Alair System to perform bronchial thermoplasty procedures for asthma patients; proceeds to fund clinical trials, build a commercial infrastructure and working capital; Piper Jaffray and Bear, Stearns & Co. Inc. are joint bookrunners; First Albany Capital Inc. and Jefferies & Co., Inc. are co-managers.

BIOVEX GROUP INC. (Nasdaq: BVEX): initial public offering of 3.4 million shares; proposed at $11 to $13 per share; Cambridge, Mass., clinical-stage biotech is focused on cancer and infectious diseases; proceeds to fund the development of OncoVEX for solid tumors and ImmunoVEX, which is in phase 1 trials; bookrunner is Janney Montgomery Scott LLC; Stifel Nicolaus is co-manager.

IMARX THERAPEUTICS INC. (Nasdaq: IMRX): initial public offering of 5 million shares; greenshoe of 750,000 shares available; proposed at $10 to $12 per share; proceeds, estimated to net $49.6 million, to repay debt, fund development and general corporate purposes; Tucson, Ariz., biotech focused on products for stroke and vascular disease; joint lead managers are CIBC World Markets (bookrunner) and Jefferies & Co.; First Albany Capital is co-manager.

LIGHT SCIENCES ONCOLOGY INC. (Nasdaq: LSON): initial public offering of 5.25 million shares; greenshoe of 787,500 shares available; proposed at $14 to $16 per share; Snoqualmie, Wash., company to use proceeds, estimated to net $71.2 million, to fund research and development and for general corporate purposes; Cowen & Co. and Wachovia Securities are joint bookrunners; Jefferies & Co. and Thomas Weisel Partners LLC are co-managers.

ROSETTA GENOMICS LTD. (Nasdaq: ROSG): initial public offering of 3 million ordinary shares; greenshoe of 450,000 shares available; proposed at $11 to $13 per share; Rehovot, Israel, biotech develops microRNA-based therapeutic to treat cancer and infectious diseases; proceeds to fund development and general corporate purposes; C.E. Unterberg, Towbin is bookrunner; Oppenheimer & Co. and Maxim Group LLC are co-managers.

TRUBION PHARMACEUTICALS INC. (Nasdaq: TRBN): initial public offering of 4 million shares; proposed at $13 to $15 per share; Seattle-based biotech develops products to treat autoimmune disease and cancer; proceeds to facilitate future access to public equity markets and obtain additional capital; Morgan Stanley is bookrunner; co-managers are Banc of America Securities LLC, Pacific Growth Equities LLC and Lazard Capital Markets.

WEEK OF OCT. 23

ACHILLION PHARMACEUTICALS (Nasdaq: ACHN): initial public offering of 4.5 million shares; greenshoe of 675,000 shares available; proposed at $14 to $16 per share; New Haven, Conn., biotech focused on infectious diseases such as HIV and hepatitis C, to use proceeds for drug development; Cowen & Co. (bookrunner) and CIBC World Markets are joint leads; JMP Securities is co-manager.

CADENCE PHARMACEUTICALS INC. (Nasdaq: CADX): initial public offering of 6 million shares; greenshoe of 900,000 shares available; proposed at $11 to $13 per share; San Diego-based biotech has developed IV APAP, an intravenous formulation of acetaminophen for pain and fever, and Omigard for device, surgical wound and burn-related infections; proceeds to fund clinical trials, manufacturing and working capital; underwriters are Merrill Lynch & Co. Inc., Deutsche Bank Securities Inc., Pacific Growth Equities, LLC and JMP Securities LLC.

CATALYST PHARMACEUTICAL PARTNERS INC. (Nasdaq: CPRX): initial public offering of 3 million shares; greenshoe of 450,000 shares available; proposed at $11 to $13 per share; Coral Gables, Fla., company develops prescription drugs to treat addiction; proceeds to fund clinical trials, and general corporate purposes; First Albany Capital Inc. and Stifel, Nicolaus & Co. are joint bookrunners.

IPOs ON THE HORIZON

ACOLOGIX INC. (Tokyo): initial public offering; proceeds estimated at $115 million; stock to be listed on the Mothers Section of the Tokyo Stock Exchange; underwriters, the number of shares to be offered and the price range have not been determined; Hayward, Calif., biotech focused on osteo-renal diseases; proceeds primarily to fund clinical trials, prepare a sales and marketing organization and general corporate purposes.

ACTIVBIOTICS INC. (Nasdaq ACTV): initial public offering; proceeds estimated at $46 million; Lexington, Mass., biotech focused on inflammatory diseases and bacterial infections; HSBC Securities (USA) Inc. is bookrunner; Needham Co. LLC is joint lead manager; BMO Capital Markets Corp. and Susquehanna Financial Group LLLP are co-managers.

AFFYMAX INC. (Nasdaq: AFFY):initial public offering; proceeds estimated at $115 million; Palo Alto, Calif., biotech focused on peptide-based drugs for chronic kidney disease and cancer; proceeds to support research and development as well as general corporate purposes; Morgan Stanley is bookrunner; Cowen & Co. is joint lead manager; Thomas Weisel Partners LLC and RBC Capital Markets as co-managers.

AMICUS THERAPEUTICS INC. (Nasdaq: AMTX): initial public offering; proceeds estimated at $86.25 million; Cranbury, N.J., biotech develops small molecule, orally active pharmacological chaperones for the treatment of human genetic diseases; Morgan Stanley is bookrunner; Goldman, Sachs & Co. is joint lead manager; Pacific Growth Equities, LLC is co-manager.

AMPHASTAR PHARMACEUTICALS INC. (Nasdaq: AMPR): initial public offering; proceeds estimated at $115 million; Rancho Cucamonga, Calif., company has 66 generic and branded injectable and inhalation products in the market; proceeds to fund continued product development, to upgrade manufacturing operations and for general corporate purposes; underwriters are Lehman Brothers, UBS Investment Bank (joint books) and Citigroup Global Markets Inc.

ARTES MEDICAL INC. (Nasdaq: ARTE): initial public offering; proceeds estimated at $75 million; San Diego medical technology company develops injectable aesthetic products for dermatology and plastic surgery markets; proceeds for sales and marketing, growth of manufacturing capabilities and clinical studies; Cowen & Co. and Lazard Capital Markets are joint bookrunners; Stifel Nicolaus is co-manager.

EMERGENT BIOSOLUTIONS INC. (Nasdaq: EBSI): initial public offering; proceeds estimated at $86.25 million; each share will include one series A junior participating preferred stock purchase right; Gaithersburg, Md., biotech develops immunobiotics; proceeds to fund clinical trials, preclinical testing manufacturing facilities and general corporate purposes; J.P. Morgan Securities Inc. is bookrunner; Cowen and Co. LLC is joint lead; HSBC Securities (USA) Inc. is co-manager.

HANSEN MEDICAL INC. (Nasdaq: HNSN): initial public offering; proceeds estimated at $86.25 million; Mountain View, Calif., company develops and manufactures medical robotics designed to position, manipulate and control catheters and catheter-based technologies; proceeds for sales, marketing and general corporate purposes; Morgan Stanley & Co. and J.P. Morgan Securities Inc. are joint bookrunners; Thomas Weisel Partners LLC and Leerink Swann & Co. are co-managers.

MOLECULAR INSIGHT PHARMACEUTICALS INC. (Nasdaq: MIPI): initial public offering; proceeds estimated at $57.5 million; Cambridge, Mass.-based company develops molecular imaging pharmaceuticals and radiotherapeutics targeting cardiology, oncology and neurology; Piper Jaffray and SG Cowen & Co. are joint bookrunners; Oppenheimer & Co. and Roth Capital Partners are co-managers.

OBAGI MEDICAL PRODUCTS INC. (Nasdaq: OMPI): initial public offering; proceeds estimated at $86.25 million; Long Beach, Calif.-based special pharmaceutical company is focused on the aesthetic and therapeutic skin health markets; proceeds to increase the scope of research and development programs and for general corporate purposes; JPMorgan is bookrunner; CIBC World Markets is joint lead; Thomas Weisel Partners LLC and Robert W. Baird & co. are co-managers.

OCULUS INNOVATIVE SCIENCES INC. (Nasdaq: OCLS): initial public offering; proceeds estimated at $80.5 million; Petaluma, Calif.-based biotech develops products to prevent infection in chronic and acute wounds; proceeds to expand sales and marketing, fund clinical trials and general corporate purposes; A.G. Edwards and Jefferies & Co. are joint bookrunners and First Albany Capital and C.E. Unterberg, Towbin are co-managers.

PERLEGEN SCIENCES INC. (Nasdaq: PERL): initial public offering; proceeds estimated at $115 million; Mountain View, Calif., biotech, formed in 2000 as a spinoff from Affymetrix Inc., develops genetically targeted medicines for metabolic, cardiovascular, central nervous system and inflammatory diseases; joint lead managers are Lehman Brothers (bookrunner) and Deutsche Bank Securities; co-managers are Piper Jaffray and Allen & Co. LLC.

PHARMASSET INC. (Nasdaq: VRUS): initial public offering; proceeds estimated at $75 million; Princeton, N.J., biotech is working on novel drugs to treat viral infections; proceeds for clinical development programs. Banc of America Securities LLC and UBS Investment Bank are joint bookrunners; JMP Securities is co-manager.

SENORX INC. (Nasdaq: SENO): initial public offering; proceeds estimated at $86.25 million; Aliso Viejo, Calif.-based company is focused on medical devices for the diagnosis of breast cancer; proceeds to repay interest on notes that will be converted into stock, and research and development; Banc of America Securities and Citigroup are joint bookrunners; Cowen & Co. and First Albany Capital are co-managers.

SUCAMPO PHARMACEUTICALS INC. (Nasdaq: SCMP): initial public offering; proceeds estimated at $86.25 million; Bethesda, Md., biotech develops drugs based on prostones, a class of compounds derived from functional fatty acids in the human body; proceeds to fund development of Amitiza for gastrointestinal indications, other development activities; Banc of America Securities LLC, Deutsche Bank Securities (joint books), Leerink Swann & Co.

VIRAGEN INC. (Amex: VRA): 67 million units, consisting of one share plus one five-year warrant to purchase one share; greenshoe for 5.36 million units available; units to be listed on the American Stock Exchange under the ticker VRA.U and, when separated, the warrants are to trade under the ticker VRA.WS; Plantation, Fla., biotech focused on therapeutic proteins to treat cancers and viral diseases; proceeds earmarked to repay debt, research and development, sales and marketing and working capital; bookrunner is Dawson James Securities, Inc.

XTENT INC. (Nasdaq: XTNT): initial public offering; proceeds estimated at $103.5 million; Menlo Park, Calif., medical devices firm develops drug-eluting stents for coronary artery disease; proceeds for clinical trials and expanding commercial infrastructure; Piper Jaffray & Co. is bookrunner; Cowen and Co. LLC, Lazard Capital Markets LLC and RBC Capital Markets Corp. are co-managers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.